Novaseek is pursuing CROs and pharmas to employ its clinical data platform, Clinical Data Network for Research (CDNR), said CEO Kate Torchilin in an interview with this news service at the Biotech Showcase conference in San Francisco.
The Cambridge, Massachusetts-based company currently works with two CROs, which Torchilin declined to name, adding that Novaseek is intent on forming more CRO partnerships. Novaseek also works with four large global pharmas and several biotechs and academic institutions, said Torchilin, noting that the firm hopes to triple its number of relationships with pharmas in the coming year. Novaseek is indication agnostic and could work with pharmas or CROs across a wide range of disease areas, he explained.
Torchilin pointed to other comparable collaborations in the space that Novaseek could replicate, including the recent merger of Quintiles (NYSE:Q) and IMS Health to form Quintiles IMS Holdings.
The ideal partners for Novaseek would have databases of clinical records that require data analysis or have data limitations that Novaseek's services could complement, Torchilin said. Novaseek's software platform is able to retroactively track types of patients from de-identified historical data in ways that other companies currently cannot, Torchilin said. The CDNR platform allows companies to directly interact with data and have access to real-world patient populations with the ultimate goal of increasing trial efficiency and clinical significance, he explained.
Novaseek has several different approaches to payment structures with partners, including subscriptions and licensing models with various parts of its platform, said Torchilin, adding that the company is flexible in terms of revenue models.
by Alissa Fleck in San Francisco
Comments are closed.